Shackelford Pharma

Growth Stage

PIONEERING FOR PATIENTS

Overview

Platform

Dealmaker Securities

Start Date

12/12/2022

Close Date

12/12/2023

Min. Goal

$1,500

Max. Goal

$12,520,000

Min. Investment

$1,500

Security Type

Equity - Common

Series

Series A

Funding Type

RegA+

Price Per Share

$1.50

Pre-Money Valuation

$68,195,651

Location

Vancouver, British Columbia

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B/B2C

Margin

Medium

Capital Intensity

High

Business Type

Growth

Shackelford Pharma is raising funds independently through Reg A+ crowdfunding with DealMaker Securities as the Broker-Dealer. It is a biopharmaceutical company dedicated to developing medicines for neurological diseases. The company is currently developing SP1707 as its first drug candidate as a long-acting cannabinoid formulation for patients suffering from seizures. Mark Godsy and Dr. Alan Shackelford founded Shackelford Pharma in 2018. The current crowdfunding campaign has a maximum target of $12.5 million. The campaign proceeds will be used for research and development and general working capital.

Balance Sheet

Cash and Cash Equivalents

$6,143,513

Accounts and Notes Receivable

$54,611

Total Assets

$6,411,228

Accounts Payable & Accrued Liabilities

$403,212

Long Term Debt

$0

Total Liabilities

$6,411,228

Total Stockholders' Equity

$6,008,016

Total Liabilities and Equity

$6,411,228

Statement of Comprehensive Income Information

Depreciation and Amortization

$6,552

Net Income

$-3,520,134

Earnings Per Share - Basic

$-0.09

Earnings Per Share - Diluted

$-0.09

Auditor: Dale Matheson Carr-Hilton Labonte LLP
Financials as of: 12/12/2022
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Shackelford Pharma 12/12/2023 Dealmaker Securities $68,195,651 $0 Equity - Common Active RegA+
Shackelford Pharma 08/20/2021 Dalmore Group $37,595,931 $9,303,845 Equity - Common Funded RegA+
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$12.42 /month
billed annually
Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings (excluding risk)
Advanced company search ( with ratings)
Markets page filters and historical industry data
Get Edge Annual

Edge Pro

$41.58 /month
billed annually
Full site access including KingsCrowd's qualitative analyst reports.
Plan Includes:
Everything in Edge, plus
Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
Search and filter based on Analyst Reports
In-depth risk ratings for every raise
Get Edge Pro Annual
Already a member? Log in here.

Create your first portfolio

Create your very own investment portfolio on KingsCrowd.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Shackelford Pharma on DealMaker Securities 2022
$
Platform: Dealmaker Securities
Security Type: Equity - Common
Valuation: $68,195,651
Invest in a different round for this company? Use my investment date to determine which raise I invested in.

Follow company

Follow Shackelford Pharma on DealMaker Securities 2022